SCH-50911 is a selective GABAB antagonist developed by Schering-Plough Corporation. Its main applications are in pharmacology research. SCH-50911 also acts as an anticonvulsant under normal conditions, and so counteracts both the depressant and pro-convulsant effects of GHB overdose. This pharmacological profile makes SCH-50911 a promising candidate as a GHB antidote for human use, and might also make it useful for treating overdoses of other GABAB agonists such as Baclofen. References: van Nieuwenhuijzen PS, McGregor IS, Chebib M, Hunt GE. Regional Fos-expression induced by γ-hydroxybutyrate (GHB): comparison with γ-butyrolactone (GBL) and effects of co-administration of the GABAB antagonist SCH 50911 and putative GHB antagonist NCS-382. Neuroscience. 2014 Sep 26;277:700-15. doi: 10.1016/j.neuroscience.2014.07.056. Epub 2014 Aug 1. PubMed PMID: 25088910.

纯度：≥98%

CAS：733717-87-8